Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma's Medical Liaisons: From KOLs To Outcomes And Virtual Options

Executive Summary

Compliance issues, boundaries of off-label discussions and an enhanced emphasis on patient health outcomes are shaping how medical science liaisons (MSLs) engage with existing and emerging stakeholders. Scrip spoke to senior executives from UCB, GlaxoSmithKline, Novartis and Indegene, a healthcare solutions provider, among others, on the evolving role of MSLs and the potential value of hybrid models in this environment.

Advertisement

Related Content

Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097439

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel